CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Emerging SARS-CoV-2 variants with mutations in the spike protein raise concerns regarding vaccine efficacy. Here, the authors show that two spike encoding mRNA vaccines in preclinical and clinical development protect human ACE2 mice from the B.1.351 variant of concern and ancestral B BavPat1.

Guardado en:
Detalles Bibliográficos
Autores principales: Donata Hoffmann, Björn Corleis, Susanne Rauch, Nicole Roth, Janine Mühe, Nico Joel Halwe, Lorenz Ulrich, Charlie Fricke, Jacob Schön, Anna Kraft, Angele Breithaupt, Kerstin Wernike, Anna Michelitsch, Franziska Sick, Claudia Wylezich, Bernd Hoffmann, Moritz Thran, Andreas Thess, Stefan O. Mueller, Thomas C. Mettenleiter, Benjamin Petsch, Anca Dorhoi, Martin Beer
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/25c1d158976849108a4f7763b4e1755a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Emerging SARS-CoV-2 variants with mutations in the spike protein raise concerns regarding vaccine efficacy. Here, the authors show that two spike encoding mRNA vaccines in preclinical and clinical development protect human ACE2 mice from the B.1.351 variant of concern and ancestral B BavPat1.

Ejemplares similares